Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

Table 1 Cost of Afatinib, Erlotinib, and Gefitinib; and indicated dosage

TKI	Presentation	Cost at which INCan bought one month of treatment	Daily dose
Afatinib	30 tablets of 40 mg	MXN 22,950.00	40 mg
Erlotinib	30 tablets of 150 mg	MXN 24,560.40	150 mg
Gefitinib	30 tablets of 250 mg	MXN 13,532.04	150 mg

ISSN: 1471-2407